Effect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africa
This large-scale emulated target trial study in South Africa demonstrates that transitioning virally suppressed children and adolescents with HIV from efavirenz- or lopinavir/ritonavir-based regimens to dolutegravir-based antiretroviral therapy significantly reduces the risk of death or viral rebound over 12 to 24 months, strongly supporting the global shift toward dolutegravir for this population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For millions of children and teenagers living with HIV, the path to a healthy life depends on taking daily medication that keeps the virus quiet. For years, the standard treatment for older children and adolescents was a regimen built around a drug called efavirenz, while younger children often took a different medication known as ritonavir-boosted lopinavir. These drugs worked well, but they came with significant drawbacks: they could be difficult to swallow, caused unpleasant side effects, and sometimes required complex dosing schedules. A newer, more forgiving drug called dolutegravir has emerged as a superior option, offering better protection against the virus and fewer side effects. Global health programs are now in the middle of a massive shift, moving patients from the older drugs to this new one. However, a critical question remained unanswered: does switching a child who is already doing well—whose virus is already suppressed and undetectable—to this new drug actually help them stay healthy, or does the act of switching itself risk disrupting their routine and causing the virus to return?
To answer this, researchers in South Africa turned to a vast digital record of care. They looked at data from 724 clinics across the KwaZulu-Natal province, a region with one of the highest concentrations of people living with HIV in the world. The team focused on nearly 37,000 children and adolescents who were already taking their medication successfully, with their viral loads low enough to be considered controlled. They wanted to see what happened when these children transitioned to the new dolutegravir-based treatment compared to those who stayed on their original regimens. Because it is no longer possible to run a randomised trial where some children are told to stay on older, less effective drugs, the researchers used a sophisticated method to mimic a fair comparison using real-world data. They tracked these young people over time, looking specifically at whether they remained virus-free or if the virus began to replicate again, or if they passed away.
The results of this large-scale analysis were clear and compelling. In every group studied, the children who switched to the dolutegravir regimen had significantly better outcomes than those who remained on their previous medication. For the older adolescents who had been taking efavirenz, the risk of the virus becoming detectable again or of death within a year dropped from nearly 12 percent to about 7 percent for those who made the switch. The improvement was even more pronounced for those who had been on the older, more complex regimens. Among older children taking the ritonavir-boosted lopinavir, the risk of a bad outcome fell from nearly 18 percent to just under 10 percent after switching. The benefit was equally strong for the youngest children, where the risk dropped from roughly 16 percent to 7 percent. These gaps in health outcomes did not close; they widened over time, with the benefits becoming even more apparent after two years of follow-up.
The study suggests that the advantages of the new drug extend far beyond just treating active infections. Even for children who were already stable, the switch to dolutegravir provided a stronger shield against the virus rebounding. This finding is crucial because it addresses a common hesitation in public health: the fear that changing a working system might break it. The data shows the opposite is true. The transition to the new treatment did not disrupt care; it strengthened it. The researchers noted that the new drug likely offers a more forgiving environment for adherence, meaning that if a child misses a dose or faces other challenges, the new medication is less likely to fail than the older options. This is particularly important for adolescents, who often face unique challenges in sticking to daily routines.
The implications of these findings are immediate and practical. They provide strong evidence that health programs should continue and accelerate the move to dolutegravir for all children and adolescents, regardless of whether they are just starting treatment or have been on medication for years. The study confirms that the new drug is not just a replacement, but an upgrade that improves the odds of long-term health for a vulnerable population. By moving away from older, more difficult regimens, health systems can offer a simpler, more effective path forward, ensuring that the next generation of children living with HIV has the best possible chance to thrive. The evidence gathered from thousands of real-world cases suggests that the transition is not just safe, but essential for maintaining the hard-won gains in viral suppression.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.